PERCORTEN Drug Patent Profile
✉ Email this page to a colleague
When do Percorten patents expire, and when can generic versions of Percorten launch?
Percorten is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in PERCORTEN is desoxycorticosterone acetate. There are two drug master file entries for this compound. Additional details are available on the desoxycorticosterone acetate profile page.
US Patents and Regulatory Information for PERCORTEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PERCORTEN | desoxycorticosterone pivalate | INJECTABLE;INJECTION | 008822-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | PERCORTEN | desoxycorticosterone acetate | PELLET;IMPLANTATION | 005151-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
